Search clinical trials for: E2020

Total 39 results

Eisai Co., Ltd.

Completed

Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease

Alzheimer's Type Dementia

Japan
Eisai Inc.

Completed

A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia

Alzheimer's Type Dementia

Japan
Eisai Co., Ltd.

Completed

A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase

Dementia With Lewy Bodies (DLB)

Japan
Eisai Co., Ltd.

Completed

A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease

Dementia Associated With Cerebrovascular Disease

Korea, Republic of
Eisai Co., Ltd.

Completed

A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)

Lewy Body Disease | Dementia, Lewy Body

Japan
Eisai Co., Ltd.

Completed

A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies

Dementia With Lewy Bodies (DLB)
Eisai Co., Ltd.

Completed

A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)

Dementia With Lewy Bodies (DLB)

Japan
National Cancer Institute (NCI)

Completed

A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas

Adult Anaplastic Astrocytoma | Adult Giant Cell Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
Eisai Limited

Completed

A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease

Alzheimer's Type Dementia

China
Eisai Limited

Completed

A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020

Alzheimer Disease

Japan
Eisai Inc.

Completed

Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease

Dementia, Vascular

United States
Eisai Inc.

Completed

An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis

Migraine Headache

United States
University of Manitoba
Canadian Institutes of Health Research (CIHR)

Recruiting

Examining the Impact of a Self-compassion Intervention on Physical Activity Behaviour Among People With Prediabetes

PreDiabetes

Canada
University of Manitoba
Mitacs

Withdrawn

Reframe Your Pain: A Feasibility and Acceptability Study

Low Back Pain
University of Manitoba
Canadian Institutes of Health Research (CIHR)

Completed

Is Teaching People to be Self-compassionate Feasible and Acceptable for People Who Are Pre-diabetic

PreDiabetes

Canada
Eisai Inc.
Pfizer

Completed

The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility

Mild to Severe Alzheimer's Disease

United States
Eisai Inc.

Completed

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

Mild Cognitive Impairment

United States
Eisai Inc.
Pfizer

Completed

EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)

Alzheimer's Disease

United States
Eisai Inc.
Pfizer

Completed

Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease

Dementia | Alzheimer's Disease

United States, Canada, United Kingdom, Australia, France, Ireland
Eisai Co., Ltd.

Completed

Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.

End-Stage Renal Disease

Japan
Eisai Limited

Completed

The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia

Dementia With Parkinson's Disease

Germany, Ireland
Eisai Inc.
Pfizer

Withdrawn

Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease

Severe Alzheimer's Disease

United States
Eisai Limited

Completed

The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

Cognitive Impairment

United States, Spain, Australia
Eisai Co., Ltd.

Completed

A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.

Down Syndrome

Japan
Eisai Inc.

Completed

Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers

Alzheimer's Disease

France
Eisai Co., Ltd.

Completed

A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males

Healthy Adult

Japan
Eisai Co., Ltd.

Completed

A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult Males

Healthy Adult

Japan
Eisai Inc.
Pfizer

Completed

Neural Correlates In Mild Alzheimer's Disease

Alzheimer's Disease

United States
Eisai Inc.
Eisai Limited

Completed

Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

Attention Impairment

United States, Netherlands, France, Spain, United Kingdom, Germany, Argentina, Canada, Australia, Chile
Eisai Inc.
Pfizer

Completed

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

Down Syndrome

United States
Eisai Inc.
Pfizer

Terminated

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

Cognitive Dysfunction | Down Syndrome

United States
Eisai Inc.
Pfizer

Terminated

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

Cognitive Dysfunction | Down Syndrome

United States
Eisai Inc.
Pfizer

Terminated

Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial

Down Syndrome

United States
Eisai Inc.
Pfizer

Completed

The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)

Memory Loss

United States
University Health Network, Toronto
Eisai Inc.

Completed

Safety of Donepezil in Patients With Dementia Associated With Cerebrovascular Disease

Dementia Associated With Cerebrovascular Disease

Canada
Eisai Inc.
Eisai Limited

Completed

Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease

Alzheimer's Disease

United States
Eisai Inc.
Eisai Limited

Completed

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

Alzheimer's Disease

United States
University Health Network, Toronto
Qatar University; York University; International Council of Cardiovascular Prevention...

Enrolling by invitation

International CR Registry (ICRR)

Coronary Artery Disease | Heart Failure | Acute Coronary Syndrome

Qatar
Eisai Inc.

Completed

Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia

Parkinson's Disease | Dementia

United Kingdom

3

Subscribe